J&J suffers setback over heart-stent price cap in U.K.

07/23/2008 | Bloomberg

The British National Institute for Health and Clinical Excellence has denied an appeal from Johnson & Johnson's Cordis unit against a ruling that limits the price of drug-coated stents to no more than $599 above the cost of bare-metal stents. Drug-eluting devices "will continue to be an important treatment option for patients who would be at high risk of requiring further interventions if a bare-metal stent was used instead," NICE CEO Andrew Dillon said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX